Researchers from Edith Cowan University (ECU) are leading ground-breaking global trials which could save lives by changing how we treat cancer in the near future. They found that adding an mRNA vaccine tailored to suit an individual’s tumour genetics to common immunotherapy significantly improves survival and disease recurrence rates among people who’d had high-risk skin cancers removed.

Evonik recently held a groundbreaking ceremony for the establishment of a large-scale lipids production facility in Lafayette, Indiana, USA. The new unit aims to offer critical excipients for the development of mRNA vaccines and other nucleic acid therapies.

Located in Hanau, Germany, Evonik’s new GMP facility will produce pharmaceutical lipids for advanced and pharmaceutical drug delivery applications. It will also offer lipids for clinical and small-scale commercial manufacturing.

With an aim to expand its business in Asia, Biontech has acquired one of Novartis’ GMP-certified manufacturing facilities in Singapore. With this move, the company intends to establish its first mrna facility in the country.

A Large, real-world study found that Covid-19 vaccination is more effective than natural immunity in protecting against all causes of death, hospitalization and emergency department visits.

How does a cell “decide” what type of cell to become? The question of cell fate has been explored for decades now, especially in the context of stem cell biology, but there are still gaps in our understanding. Scientists at EPFL now found that lipids play a major role in this process.

A team led by scientists at the University of Birmingham has come a step closer to uncovering the purpose of a distinctive set of modifications found at the beginning of messenger RNA which have long remained a fundamental mystery in molecular biology.

Under a 15-year strategic collaboration agreement signed between Moderna and Thermo Fisher Scientific, both the firms will work together to ensure large-scale manufacturing of Moderna’s Covid-19 vaccine, and other investigational mRNA drugs in the USA.

A leading biopharmaceutical company has selected Bilfinger to support the development of its new production facility for mRNA (messenger ribonucleic acid)-based active ingredients. Under the terms of the contract, Bilfinger will deliver prefabricated skids i.e. molecular biological reactors as well as build the plant’s process piping systems.

German biopharmaceutical company Biontech announced plans for the development of the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022.